Autolus Therapeutics plc — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company is a clinical-stage biopharmaceutical developer of programmed T-cell therapies and voluntarily filed this quarterly report as a foreign private issuer. It has no approved products and generated no commercial product sales.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| License revenue | $10.1 million | $1.3 million; up $8.8 million |
| Research and development expense | $30.7 million | $27.4 million; up 12% |
| General and administrative expense | $18.2 million | $9.3 million; up 96% |
| Operating expenses, net | $38.8 million | $39.1 million |
| Interest expense | $19.3 million | $4.9 million |
| Net loss | $52.7 million | $39.8 million |
| Basic and diluted loss per share | $0.24 | $0.23 |
| Net cash used in operating activities | $40.5 million | $42.4 million |
| Cash and cash equivalents at period end | $758.5 million | $239.6 million at December 31, 2023 |
Q1 license revenue came from the BioNTech license agreement; the prior-year revenue primarily reflected the Cabaletta agreement. Interest income was $6.9 million, compared with $3.4 million. The filing reports no commercial gross margin; revenue is license revenue, not product sales.
Cash, cash equivalents and restricted cash totaled $759.5 million at March 31. Financing activities provided $561.4 million, principally from the February equity offering and BioNTech transactions; investing activities used $0.5 million. Total liabilities were $319.4 million, including $228.5 million of liabilities related to future royalties and milestones and $51.3 million of operating lease liabilities. The royalty-related liabilities are not presented as conventional borrowings.
Material changes versus the prior comparable period
- Net loss widened by $12.9 million. The increase in interest expense included an $8.4 million accrued-interest charge and a $10.9 million cumulative catch-up adjustment related to future royalty and milestone liabilities.
- G&A expense rose $8.9 million, reflecting increased staffing, commercial-readiness activity, professional fees and information-technology costs. R&D expense rose $3.3 million, mainly due to facilities, staffing and clinical-trial costs.
- Cash increased substantially following a February underwritten offering that generated $326.8 million net and a BioNTech private placement that generated $193.8 million net. These transactions issued 91.7 million ordinary shares in total; period-end outstanding shares were approximately 266.0 million.
Outlook, management commentary and risks
- Management expects March 31 cash and cash equivalents to fund current and planned operating expenses and capital expenditures for at least 12 months from the financial statements’ issuance date. It expects continued operating losses and says additional funding will be needed before cash breakeven. No specific revenue, earnings or cash-use guidance was provided.
- The FDA BLA for obe-cel in relapsed/refractory adult B-cell ALL was submitted in November 2023; the PDUFA target action date is November 16, 2024. The EMA accepted the marketing authorization application in April 2024; a U.K. submission was planned for the second half of 2024. The company reported that its Stevenage facility received manufacturing authorization and a GMP certificate in March 2024.
- Management expects R&D and G&A costs to increase as it advances trials, operates its manufacturing facility and prepares for potential commercialization. Clinical, regulatory, manufacturing, reimbursement, competition and financing risks remain material.
- BioNTech paid $40 million upfront for a share of future obe-cel revenues; Autolus owes a low-single-digit percentage of annual net sales, potentially increasing to mid-single digits in exchange for up to $100 million in milestone payments tied to specified regulatory events and BioNTech’s election. BioNTech also received licenses and options; maximum aggregate payments under the agreement could reach $582 million if all options are exercised and milestones achieved, but these amounts are contingent, not assured.
- Disclosure controls and procedures were assessed as ineffective due to two material weaknesses: historical accounting for U.K. SME tax credits and controls over complex accounting transactions, including the BioNTech agreements. Remediation is ongoing. The filing warns that weaknesses could affect timely and accurate reporting or lead to restatements.
- Other risks include foreign-exchange exposure (the company recorded a $1.7 million foreign-exchange loss in Q1), reliance on U.K. R&D tax credits, and $9.9 million of capital purchase commitments expected to be incurred within one year. No material litigation or contingency reserves were reported.
Most important facts for investors to verify
- Progress and timing of FDA review of obe-cel, including the November 16, 2024 target action date, and the status of European and U.K. regulatory submissions.
- Cash burn and runway against increasing development and commercialization spending; management’s runway estimate is based on assumptions and does not imply cash breakeven.
- Remediation and testing of both material weaknesses, particularly controls for complex transactions and the accounting judgments behind royalty-related liabilities and interest expense.
- Potential dilution and BioNTech’s rights: share issuance, any additional share purchase tied to a manufacturing and commercial services agreement, and the contingent economics of licenses, options and obe-cel royalties.
- Clinical results, manufacturing readiness, commercial execution and the assumptions used to estimate future royalty payments and cumulative catch-up adjustments.